From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
Author:
Affiliation:
1. Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA
Publisher
Oxford University Press (OUP)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology
Link
http://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvab231/39585581/cvab231.pdf
Reference15 articles.
1. Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis;Ridker;Circ Res,2019
2. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker;N Engl J Med,2017
3. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial;Ridker;Lancet,2018
4. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS);Ridker;Eur Heart J,2018
5. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease;Ridker;Circ Res,2021
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis;Pharmacological Research;2024-02
2. Fatal attractions that trigger inflammation and drive atherosclerotic disease;European Journal of Clinical Investigation;2024-01-29
3. C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden;Current Opinion in Lipidology;2024-01-26
4. Inflammation as a New Therapeutic Target among Older Patients with Ischemic Heart Disease;Journal of Clinical Medicine;2024-01-09
5. Targeting inflammation in atherosclerosis: overview, strategy and directions;EuroIntervention;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3